Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Treatment of PC12 cells with nerve growth factor (NGF) induces a rapid increase in tyrosine phosphorylation of multiple cellular proteins. Expression of a dominant inhibitory Ras mutant specifically blocked NGF- and
TPA
-induced tyrosine phosphorylation of two proteins of approximately 42 and 44 kd. Conversely, expression of an oncogenic variant of Ras induced tyrosine phosphorylation of the same 42 and 44 kd proteins. The 44 kd protein was immunoprecipitated with an antibody directed against extracellular signal-regulated kinase 1/
mitogen-activated protein kinase
(
MAPK
) and the 42 kd protein comigrated with a 42 kd
MAPK
, indicating that at least one and probably both Ras-regulated phosphoproteins are MAPKs. In addition,
MAPK
activation, as measured by in vitro phosphorylation of myelin basic protein, was also regulated by Ras. Ras was not required for NGF-induced activation of Trk or tyrosine phosphorylation of PLC-gamma 1. Thus, NGF-induced tyrosine phosphorylation occurs both prior to and following Ras action, and Ras plays a critical role in the NGF- and
TPA
-induced tyrosine phosphorylation of MAPKs.
...
PMID:Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases. 131 92
Both MAP kinases and the protein kinase p74raf-1 are activated by many growth factors in a c-ras-dependent manner and by oncogenic p21ras. We were therefore interested in determining the relationship between MAP kinases and raf. The
MAP kinase
ERK2
is activated by expression of oncogenically activated raf, independently of cellular ras. Overexpressed p74raf-1 potentiates activation of
ERK2
by EGF and
TPA
. MAP kinase kinase inactivated by phosphatase 2A treatment is phosphorylated and reactivated by incubation with p74raf-1 immunoprecipitated from phorbol ester-treated cells. We conclude that raf protein kinase is upstream of MAP kinases and is either a MAP kinase kinase kinase or a MAP kinase kinase kinase kinase.
...
PMID:Activation of the MAP kinase pathway by the protein kinase raf. 133 Mar 21
Proteins of the ras family of oncogenes have been implicated in signal transduction pathways initiated by protein kinase C (PKC) and by tyrosine kinase oncogenes and receptors, but the role that ras plays in these diverse signalling systems is poorly defined. The activity of ras proteins has been shown to be controlled in part by a cellular protein, GAP (GTPase-activating protein), that negatively regulates p21c-ras by enhancing its intrinsic GTPase activity. Thus, overexpression of GAP provides a tool for determining the step(s) in signal transduction dependent on p21c-ras activity. In this paper, we report that overexpression of GAP blocks the phorbol ester (tetradecanoyl phorbol acetate [
TPA
])-induced activation of
p42 mitogen-activated protein kinase
(
p42mapk
), c-fos expression, and DNA synthesis. GAP overexpression did not block responses to serum or fluoroaluminate. Moreover, not all biochemical events elicited by
TPA
were affected by GAP overexpression, as increased glucose uptake and phosphorylation of MARCKS, a major PKC substrate, occurred normally. Reduction of GAP expression to near normal levels restored the ability of the cells to activate
p42mapk
in response to
TPA
. These findings suggest that ras and GAP together play a key role in a PKC-dependent signal transduction pathway which leads to
p42mapk
activation and cell proliferation.
...
PMID:Regulation of tetradecanoyl phorbol acetate-induced responses in NIH 3T3 cells by GAP, the GTPase-activating protein associated with p21c-ras. 154 25
Threonine and tyrosine residue phosphorylation of a 42 kDa protein identified as
mitogen-activated protein kinase
(
MAP kinase
) was stimulated in extracts from
TPA
-pretreated cells. It is further shown that
TPA
pretreatment leads to the enhancement of an activity that will induce reactivation of dephosphorylated/inactivated
MAP kinase
. This
TPA
-induced activity induces the threonine and tyrosine phosphorylation of p42 in extracts from unstimulated cells.
...
PMID:TPA-induced activation of MAP kinase. 165 37
Mitogen-activated protein (MAP) kinase is a serine/threonine-specific protein kinase which is activated in response to various mitogenic agonists (e.g., epidermal growth factor, insulin, and the tumor promoter tetradecanoyl phorbol acetate [
TPA
]) and requires both threonine and tyrosine phosphorylation for activity. This enzyme has recently been shown to be identical or closely related to
pp42
, a protein which becomes tyrosine phosphorylated in response to mitogenic stimulation. Neither the kinases which regulate
MAP kinase
/
pp42
nor the in vivo substrates for this enzyme are known. Because MAP
MAP kinase
is activated and phosphorylated in response both to agents which stimulate tyrosine kinase receptors and to agents which stimulate protein kinase C, a serine/threonine kinase, we have examined the regulation and phosphorylation of this enzyme in 3T3-TNR9 cells, a variant cell line partially defective in protein kinase C-mediated signalling. In this communication, we show that in the 3T3-TNR9 variant cell line,
TPA
does not cause the characteristically rapid phosphorylation of
pp42
or the activation and phosphorylation of
MAP kinase
. This defective response is not due to the absence of the
MAP kinase
/
pp42
protein itself because both tyrosine phosphorylation of
MAP kinase
/
pp42
and its enzymatic activation could be induced by platelet-derived growth factor in the 3T3-TNR9 cells. Thus, the defect in these variant cells apparently resides in some aspect of the regulation of
MAP kinase
phosphorylation. Since the 3T3-TNR9 cells are also defective with respect to the
TPA
-induced increase in ribosomal protein S6 kinase, these in vivo results reinforce the earlier in vitro finding that
MAP kinase
can regulate S6 kinase activity. These findings suggest a key role for
MAP kinase
in a kinase cascade cascade involved in the control of cell proliferation.
...
PMID:Defective regulation of mitogen-activated protein kinase activity in a 3T3 cell variant mitogenically nonresponsive to tetradecanoyl phorbol acetate. 199 Feb 61
2,3,7,8-Tetrachloro-p-dioxin (TCDD) induced a modest stimulation of nuclear protein phosphorylation in explant tissue cultures in 10 min, followed by a substantial decrease in the level of total protein phosphorylation activity in the nucleus. Curiously, this TCDD-induced decline in nuclear protein phosphorylation was accompanied by an increase in cytosolic and extranuclear protein phosphorylation activity. One of the main causes for such a decrease in the protein phosphorylation activity in the nucleus appears to be related to some increase in protein phosphatase activities as judged by the counteractions of okadaic acid and Na3VO4 to the above effect. In addition, TCDD induced changes in nuclear protein kinase activities as well. Manganese-stimulated protein kinase was found to be the predominant type of nuclear protein phosphorylating activity affected by TCDD, with 60% of the total activity due to heparin-sensitive casein kinase II (CK II), a major nuclear protein kinase. The level of CK II activity in the nuclear protein preparation from adipose tissue of TCDD-treated guinea pigs (1 microgram/kg) in the presence of 100 nM heparin was only 35% of the control value after 24 hr. In addition, TCDD was found to increase the protein kinase C and
microtubule-associated protein 2 kinase
activities as early as 15 min after treatment in isolated adipose tissues in culture. Under in situ incubation conditions with explant tissues in culture, TCDD rapidly enhanced the DNA binding activity of the transcriptional factor AP-1, whereas the same treatment reduced c-Myc DNA binding activity. Genistein, a specific protein tyrosine kinase inhibitor, abolished the stimulatory effect of TCDD on AP-1 binding activity, but not on DNA binding activity of c-Myc. Phorbol ester (
TPA
) increased the binding activity of AP-1 and c-Myc, as expected. However, TCDD in combination with
TPA
caused a slight reduction in binding activity of both transcriptional factors. On the other hand, in the presence of forskolin, the stimulatory effect of TCDD on AP-1 binding activity and the inhibitory effect on c-Myc were still apparent. Okadaic acid almost abolished the binding activity of c-Myc, whereas in combination with TCDD a stimulatory effect was found. These observations are consistent with the idea that TCDD regulates the DNA binding activity of AP-1 and c-Myc mainly through modulating their states of phosphorylation by altering protein kinase and phosphatase activities.
...
PMID:Regulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) of the DNA binding activity of transcriptional factors via nuclear protein phosphorylation in guinea pig adipose tissue. 748 34
In this study, we examined the role of insulin, protein kinase C (PKC) and
mitogen-activated protein kinase
(
MAPK
) cascade in activation of protein phosphatase-1 (PP-1) by using three complementary approaches. First, differentiated L6 cells were acutely exposed to 12-O-tetradecanoylphorbol-13-acetate (
TPA
, 400 nM) to activate PKC. In these cells,
TPA
caused 32% stimulation of PP-1 activity. The PP-1 stimulation by
TPA
was comparable to stimulation by insulin (t1/2 = 1 min and EC50 = 5 nM) with a maximum effect in 5 min. The effects of insulin and
TPA
were not additive. Insulin and
TPA
also stimulated
MAPK
(> 2-fold increase over basal, with myelin basic protein as a substrate). ML-9, a myosin light chain kinase inhibitor, blocked the effects of insulin and
TPA
on both
MAPK
and PP-1 activation. In the second approach, PKC was down-regulated by chronic treatment with
TPA
. In these cells subsequent effects of insulin on
MAPK
and PP-1 activation were blocked, without an effect on basal enzyme levels. In the third approach, two selective inhibitors of PKC, calphostin and chelerythrine chloride, were used to inhibit PKC. These inhibitors completely prevented insulin and
TPA
stimulation of
MAPK
and PP-1 and blocked insulin-induced translocation of PKC to the plasma membranes. We conclude that PKC plays an important role in insulin stimulation of PP-1 via the activation of
MAPK
cascade.
...
PMID:Stimulation of protein phosphatase-1 activity by phorbol esters. Evaluation of the regulatory role of protein kinase C in insulin action. 751 82
Epidermal growth factor (EGF), 20 ng/ml, stimulated myelin basic protein (MBP) phosphorylation in crude extracts from human keratinocyte primary cultures. In order to identify the involved kinases, we separated by fast protein liquid chromatography proteins participating in MBP phosphorylation. We detected three MBP kinase activities in the keratinocyte crude extracts. The first MBP kinase activity was the only one stimulated by EGF and reacted with anti-
mitogen-activated protein kinase
(
MAPK
) antiserum recognising
p42mapk
and p44mapk isoforms. However, when protein kinase C (PKC) was either inhibited by the PKC inhibitor GF 109203X or depleted by a prolonged
TPA
treatment, the stimulation of MBP phosphorylation by EGF was strongly inhibited. The second MBP kinase activity eluted was due to a PKC isoform reacting with an anti-PKC zeta antibody, and the third was not identified. With this work, we have thus shown that, in human keratinocytes, EGF activates
MAPK
activity by a PKC-dependent pathway.
...
PMID:Epidermal growth factor stimulates mitogen-activated protein kinase by a PKC-dependent pathway in human keratinocytes. 753 73
When quiescent dog thyroid epithelial cells in primary culture are stimulated for 48 h with thyrotropin (TSH), forskolin acting through cAMP, or with cAMP-independent mitogens including epidermal growth factor (EGF), hepatocyte growth factor (HGF), and a tumor promoting phorbol ester (
TPA
), only 30-60% of cells progress through the cell cycle. A more general growth response requires the combination of EGF and TSH or forskolin. In this study we ask whether this intercellular heterogeneity in mitogen sensitivity could depend on a similar heterogeneity at early stages of the mitogenic stimulation process, i.e., at the levels of p42/p44
MAP kinase
nuclear translocation and c-Fos protein appearance. We used indirect immunofluorescence microscopy with photometric quantitation and corroborated data using Western blotting. We analyzed the double staining of c-Fos and p42/p44 MAP kinases, since the nuclear translocation of these MAP kinases has been suggested as a key step for the stimulation of c-fos transcription. (i) EGF and HGF induced c-Fos accumulation and
MAP kinase
translocation in variable fractions of the cell population that corresponded to their relative potency as mitogens. c-Fos appearance and
MAP kinase
translocation poorly correlated in individual cells. Many cells accumulated c-Fos without any detectable p42/p44
MAP kinase
translocation. The heterogeneity of proliferative responses to EGF could be due to the lack of c-Fos or
MAP kinase
responsiveness of many cells. (ii)
TPA
induced c-Fos accumulation and
MAP kinase
translocation within the whole cell population, which did not explain the heterogeneity of the growth response to this factor and showed that these events are not sufficient to elicit DNA synthesis, (iii) TSH and forskolin induced a weak c-Fos accumulation in only a minority of cells but, as previously shown, no p42/p44
MAP kinase
phosphorylation and translocation. An important c-Fos expression was thus dispensable for the strong DNA synthesis stimulation exerted by cAMP-dependent mitogens. (iv) Forskolin potentiated the EGF effect on c-Fos expression but not on p42/p44
MAP kinase
phosphorylation and translocation. This reflected the fact that EGF induced c-Fos accumulation in 90% of cells in the presence of forskolin but in 30-50% of cells in its absence. This kind of potentiation, which specifically implies an increase in the fraction of responding cells, is termed "generalization" in the present study.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Intercellular heterogeneity of early mitogenic events: cAMP generalizes the EGF effect on c-Fos protein appearance but not on MAP kinase phosphorylation and nuclear translocation in dog thyroid epithelial cells. 758 41
Phorbol ester tumor promoters (
TPA
) activate the endogenous erk/MAP kinases and Rsk S6 kinases but not the p70S6 kinase in COS cells. DNA sequences encoding the rat Rsk-1 S6 kinase (homologous to Xenopus rsk alpha), modified by insertion of a peptide epitope at the polypeptide aminoterminus, were expressed transiently in COS cells.
TPA
stimulates the 40S and peptide kinase activity of the recombinant epitope-tagged Rsk-1, as well as the extent of Rsk-1 autophosphorylation in vitro (32P-Ser >> 32P-Thr). Indications that the conformation of the recombinant Rsk-1 polypeptide is substantially changed after activation by
TPA
in situ include a retarded mobility of the Rsk-1 polypeptide on SDS-PAGE and the appearance of new 32P-peptides during autophosphorylation in vitro. All these features of the
TPA
-activated Rsk-1 S6 kinase are abolished by dephosphorylation of the kinase in vitro with Ser/Thr phosphatase-2A.
TPA
increases 32P incorporation into recombinant Rsk-1 by 2-3-fold (32P-Ser >> 32P-Thr). Peptide mapping exhibits a single major 32P-peptide in Rsk-1 isolated from unstimulated cells and 10-12 additional 32P peptides after
TPA
treatment in situ. Phosphorylation of basal or phosphatase-2A-treated recombinant Rsk-1 in vitro with erk2/
MAP kinase
increases Rsk-1 40S kinase, peptide kinase, and autophosphorylating activity, retards migration of Rsk-1 polypeptides on SDS-PAGE, and generates new sites of Rsk-1 autophosphorylation in vitro. By contrast,
TPA
-activated Rsk-1 is not altered in these properties by autophosphorylation in vitro. By contrast,
TPA
-activated Rsk-1 is not altered in these properties by phosphorylation in vitro with erk2/
MAP kinase
. Activation of Rsk-1 in situ with
TPA
diminishes by over 90% the extent of Rsk-1 phosphorylation achieved in vitro by erk2/
MAP kinase
, as compared to the parallel phosphorylation of a phosphatase-2A-treated Rsk-1; basal Rsk-1 is intermediate. Peptide maps of phosphatase-2A-treated Rsk-1 after phosphorylation in vitro with erk2/
MAP kinase
exhibit 32P-peptides that comigrate with nearly all of the 32P-peptides present in
TPA
-activated-32P Rsk-1 labeled in situ, plus several 32P-peptides characteristic of Rsk-1 autophosphorylation in vitro.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Regulation of an epitope-tagged recombinant Rsk-1 S6 kinase by phorbol ester and erk/MAP kinase. 768 67
1
2
3
4
5
6
7
8
9
10
Next >>